The imperative for more efficient clinical trial design is accentuated by the ongoing development of compelling experimental HD treatments that could modify its course, including gene‐targeted therapies to decrease the translation of mutant huntingtin protein,10 stem‐cell replacement of damaged or vulnerable brain tissue,11 as well as biological or small‐molecule drugs targeting pathophysiologic mechanisms.12 This evidence concerns the gene HTT and Huntington disease.